Trial watch: Chemotherapy with immunogenic cell death inducers

doi:10.4161/onci.23510

. 2013 Mar 1;2(3):e23510.

doi: 10.4161/onci.23510.

Trial watch: Chemotherapy with immunogenic cell death inducers

Erika Vacchelli¹, Laura Senovilla, Alexander Eggermont, Wolf Hervé Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Affiliations

PMID: 23687621
PMCID: PMC3655739
DOI: 10.4161/onci.23510

Trial watch: Chemotherapy with immunogenic cell death inducers

Erika Vacchelli et al. Oncoimmunology. 2013.

. 2013 Mar 1;2(3):e23510.

doi: 10.4161/onci.23510.

Authors

Erika Vacchelli¹, Laura Senovilla, Alexander Eggermont, Wolf Hervé Fridman, Jérôme Galon, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Affiliation

¹ Institut Gustave Roussy; Villejuif, France ; Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre, France ; INSERM, U848; Villejuif, France.

PMID: 23687621
PMCID: PMC3655739
DOI: 10.4161/onci.23510

Abstract

It is now clear that the immune system plays a critical role not only during oncogenesis and tumor progression, but also as established neoplastic lesions respond to therapy. Selected cytotoxic chemicals can indeed elicit immunogenic cell death, a functionally peculiar type of apoptosis that stimulates tumor-specific cognate immune responses. Such immunogenic chemotherapeutics include cyclophosphamide, doxorubicin and oxaliplatin (which are approved by FDA for the treatment of various hematological and solid malignancies), mitoxantrone (which is currently employed both as an anticancer agent and against multiple sclerosis) and patupilone (a microtubular poison in clinical development). One year ago, in the second issue of OncoImmunology, we discussed the scientific rationale behind immunogenic chemotherapy and reviewed the status of recent clinical trials investigating the off-label use of cyclophosphamide, doxorubicin, oxaliplatin and mitoxantrone in cancer patients. Here, we summarize the latest developments in this area of clinical research, covering both high-impact studies that have been published during the last 13 months and clinical trials that have been initiated in the same period to assess the antineoplastic profile of immunogenic chemotherapeutics.

Keywords: ATP; HMGB1; autophagy; calreticulin; dendritic cells; epothilone B.

PubMed Disclaimer

Cited by

Trial Watch: Proteasomal inhibitors for anticancer therapy.
Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Obrist F, et al. Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun. Mol Cell Oncol. 2014. PMID: 27308423 Free PMC article. Review.
Caspase-9 inhibition triggers Hsp90-based chemotherapy-mediated tumor intrinsic innate sensing and enhances antitumor immunity.
Li J, Han X, Sun M, Li W, Yang G, Chen H, Guo B, Li J, Li X, Wang H. Li J, et al. J Immunother Cancer. 2023 Dec 6;11(12):e007625. doi: 10.1136/jitc-2023-007625. J Immunother Cancer. 2023. PMID: 38056894 Free PMC article.
Digital Pathology for Better Clinical Practice.
Hijazi A, Bifulco C, Baldin P, Galon J. Hijazi A, et al. Cancers (Basel). 2024 Apr 26;16(9):1686. doi: 10.3390/cancers16091686. Cancers (Basel). 2024. PMID: 38730638 Free PMC article. Review.
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2015 Feb 3;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. Oncoimmunology. 2015. PMID: 25949870 Free PMC article. Review.
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2014 Jan 1;3(1):e27048. doi: 10.4161/onci.27048. Oncoimmunology. 2014. PMID: 24605265 Free PMC article. Review.

See all "Cited by" articles

References

1. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–20. doi: 10.1038/cdd.2011.96. - DOI - PMC - PubMed
1. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007;14:1237–43. doi: 10.1038/sj.cdd.4402148. - DOI - PubMed
1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012 doi: 10.1146/annurev-immunol-032712-100008. In press. - DOI - PubMed
1. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798–804. doi: 10.1016/j.cell.2010.02.015. - DOI - PubMed
1. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. doi: 10.1038/nm1523. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–20. doi: 10.1038/cdd.2011.96. - DOI - PMC - PubMed

[2] Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–20. doi: 10.1038/cdd.2011.96. - DOI - PMC - PubMed

[3] Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007;14:1237–43. doi: 10.1038/sj.cdd.4402148. - DOI - PubMed

[4] Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007;14:1237–43. doi: 10.1038/sj.cdd.4402148. - DOI - PubMed

[5] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012 doi: 10.1146/annurev-immunol-032712-100008. In press. - DOI - PubMed

[6] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012 doi: 10.1146/annurev-immunol-032712-100008. In press. - DOI - PubMed

[7] Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798–804. doi: 10.1016/j.cell.2010.02.015. - DOI - PubMed

[8] Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140:798–804. doi: 10.1016/j.cell.2010.02.015. - DOI - PubMed

[9] Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. doi: 10.1038/nm1523. - DOI - PubMed

[10] Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. doi: 10.1038/nm1523. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Trial watch: Chemotherapy with immunogenic cell death inducers

Affiliation

Trial watch: Chemotherapy with immunogenic cell death inducers

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials